Last reviewed · How we verify
bevacizumab, capecitabine, oxaliplatin
bevacizumab, capecitabine, oxaliplatin is a Small molecule drug developed by Grupo Espanol Multidisciplinario del Cancer Digestivo. It is currently in Phase 2 development. Also known as: bevacizumab (Avastin®), capecitabine (Xeloda®), oxaliplatin.
At a glance
| Generic name | bevacizumab, capecitabine, oxaliplatin |
|---|---|
| Also known as | bevacizumab (Avastin®), capecitabine (Xeloda®), oxaliplatin |
| Sponsor | Grupo Espanol Multidisciplinario del Cancer Digestivo |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- Pan Tumor Rollover Study (PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (PHASE2)
- Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer (PHASE3)
- A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bevacizumab, capecitabine, oxaliplatin CI brief — competitive landscape report
- bevacizumab, capecitabine, oxaliplatin updates RSS · CI watch RSS
- Grupo Espanol Multidisciplinario del Cancer Digestivo portfolio CI
Frequently asked questions about bevacizumab, capecitabine, oxaliplatin
What is bevacizumab, capecitabine, oxaliplatin?
bevacizumab, capecitabine, oxaliplatin is a Small molecule drug developed by Grupo Espanol Multidisciplinario del Cancer Digestivo.
Who makes bevacizumab, capecitabine, oxaliplatin?
bevacizumab, capecitabine, oxaliplatin is developed by Grupo Espanol Multidisciplinario del Cancer Digestivo (see full Grupo Espanol Multidisciplinario del Cancer Digestivo pipeline at /company/grupo-espanol-multidisciplinario-del-cancer-digestivo).
Is bevacizumab, capecitabine, oxaliplatin also known as anything else?
bevacizumab, capecitabine, oxaliplatin is also known as bevacizumab (Avastin®), capecitabine (Xeloda®), oxaliplatin.
What development phase is bevacizumab, capecitabine, oxaliplatin in?
bevacizumab, capecitabine, oxaliplatin is in Phase 2.
Related
- Manufacturer: Grupo Espanol Multidisciplinario del Cancer Digestivo — full pipeline
- Also known as: bevacizumab (Avastin®), capecitabine (Xeloda®), oxaliplatin
- Compare: bevacizumab, capecitabine, oxaliplatin vs similar drugs
- Pricing: bevacizumab, capecitabine, oxaliplatin cost, discount & access